MDGEF News Alert Medigene Ag (MDGEF) 4.9000 09/28/2014 19:26

New Post Public Reply Private Reply Replies (0) Message Board

Sep 28, 2014 at 8:26 PM

Medigene Ag (MDGEF) 4.9000 $MDGEF

T-Cell Leukemia Therapeutics Pipeline Review 2014 - 15 Drug Profiles from 10 Leading Pharma Companies
M2 - Wed Sep 10, 10:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shcdvv/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Sanofi - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - Applied Immune Technologies Ltd Drug Profiles - alemtuzumab - mogamulizumab - lenalidomide - PF-03084014 - BMS-906024 - PCI-34051 - NK-314 - Recombinant Protein for CNS, Oncology, Hematological Disorders and Metabolic Disorders - Anti-TCR Monoclonal Antibodies for Leukemia and Autoimmune Disease - MMIG-202 - INA-01 - SL-101 - Antibody Targeting HLA-A2 for Neurology, Infectious Diseases and Oncology - Synthetic Peptide for Oncology and Male health - Cell Therapy to Target CD38 for cancer For more information visit http://www.researchandmarkets.com/research/sh...l_leukemia

Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Rheumatoid Arthritis Report - Drug Pipeline Review
M2 - Tue Sep 03, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw6rsc/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis. - A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Featured - Alcon, Inc. - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Amgen Inc. - Antares Pharma, Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Inovio Biomedical Corporation - MedImmune LLC - Isis Pharmaceuticals, Inc. - Biotest AG - Merck & Co., Inc. - Santen Pharmaceutical Co., Ltd. - Ablynx - Emergent BioSolutions Inc. - Novo Nordisk A/S - Infinity Pharmaceuticals, Inc. - Albany Molecular Research, Inc. - Plexxikon Inc. - ViaCord - arGentis Pharmaceuticals, LLC - Reliance Life Sciences Pvt. Ltd. - MediGene AG For more information visit http://www.researchandmarkets.com/research/xw6rsc/rheumatoid

Warts - Pipeline Review, H2 2012
M2 - Tue Jan 22, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g637jc/warts_pipeline) has announced the addition of Global Markets Direct's new report "Warts - Pipeline Review, H2 2012" to their offering. 'Warts - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Warts, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Warts. Scope - A snapshot of the global therapeutic scenario for Warts. - A review of the Warts products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Warts pipel

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chicken Salad Chick Expands in PA with Collegeville Launch

Chicken Salad Chick Expands Further into Pennsylvania Hot off the grill! If you're in Pennsylvania, especially around Collegeville, you might want to perk up. Chicken Salad Chick, that quirky Southern-style restaurant chain that's all about—you guessed it—chicken salad, is doubling down on its presence in the state. Come November 18, chicken enthusiasts can graze on...

Simform's AI Innovations Earns Microsoft Award Nod

Riding the AI Wave with Simform In the chaotic world of AI and tech partnerships, earning recognition from a powerhouse like Microsoft ain't your run-of-the-mill achievement. Simform being recognized as a finalist for the 2026 Microsoft Innovate with Azure AI Apps and Agents Partner of the Year Award is a big deal, not just for them, but as a beacon of inspiration for...

Housing Markets Realign: Shifting Generational Burdens

Riding the Generational Equity Wave Here's a kicker for you—the housing game has warped in ways that have flummoxed even the sharpest minds nodding along at economic seminars. Elder millennials back in the early 30s bracket once rode high with those mythical low mortgage rates—magic numbers scratching the underbelly of 3%, if you can believe it. But in today's...

Halfpricesoft's Bold Move: $169 One-Time Check Printing

Breaking Away From the Subscription Cycle When's the last time you saw a price that didn't make you groan? Halfpricesoft.com seems to have stumbled upon the magic number with their $169 flat-rate deal. You might think this feels like one of those golden eggs in a nest of subscription fatigue—and you'd be right. As inflation ramps up costs, especially for small...

Smart Radon Monitoring Expands: X-Sense at Lowe's

X-Sense Gains Ground in Home Safety Well, here it is, folks. The shift towards smart radon detection just took a gigantic leap forward—right into your everyday trip to Lowe's. X-Sense's XR0A-iR is putting radon monitoring on the map, available now across U.S. Lowe's stores at a cool $99.99. Think of it: radon detection moving as common as your bulk bag of mulch. Why...

Kargo's Tech Boosts Profit on Seafood Supply Chain

Revolutionizing Seafood Logistics with Kargo You'd think managing seafood shipments would be a simpler gig than charting ocean routes, but think again. Northern Wind, a major player in seafood processing, just proved the power of tech in an old-school business by partnering with a slick AI outfit called Kargo. Their facility in New Bedford, Massachusetts now magically...

Avoid Pitfalls: Key Steps for Injury Claims Success

For anyone in West Virginia nursing wounds and pondering a lawsuit, it's crucial to sidestep the landmines that could blow your case out of the water before it even reaches a courtroom. Understanding Timing and Documentation Right off the bat, Frank Walker, a seasoned attorney in personal injury, highlights the dangers of delaying medical treatment. This mistake leaves a...

Drowsy Driving Forum Spurs United Call for Safety Action

A Fresh Coalition Against a Familiar Foe On a brisk late October day, the National Sleep Foundation (NSF) pulled together a motley crew of road safety veterans, vehicle makers, crash sniffers, and sleep legends at the National Press Club. This wasn't just another talkfest. With an estimated 61% of U.S. adults reportedly driving while half-asleep, something finally shook...

Lululemon Lawsuit Looms: Investors Face Key Decisions

Seems Lululemon just tripped on its yoga mat. When a company like Lululemon Athletica, Inc (NASDAQ:LULU) sees a 17.38% slide in stock, every savvy investor knows there's more beneath the surface. Squarely in the crosshairs of a securities fraud class action, the brand synonymous with upscale athleisure faces harsh scrutiny. And the deadline's ticking—even the suits know...

Kia's Double Win: Telluride and K4 Grab Buzz Awards

Kia's Major Scoops in the Automotive Scene If you've been hawking the auto industry lately, Kia's latest accolades probably caught your eye. In what seems like a feather in their cap, the 2027 Kia Telluride and the 2026 K4 Hatchback nabbed victories at the Second Annual Buzz Awards. CarBuzz, HotCars, and TopSpeed—the trio of car gurus who know a thing or two about...